There is a recent update in WHO classification of pancreatic neuroendocrine neoplasms (PanNENs). Our aim is to analyse the latest management for patients with PanNENs according to the current classification of these neoplasms. The primary treatment is curative surgery and the surgical procedures depend on size, location, and histopathology of the tumour. Even if tumour has metastases, debulking surgery or resection of the primary lesion could improve the prognosis of these patients. Systemic medication is indicated in patients with unresectable primary and/or distant metastatic lesions. As new antineoplastic agents have been approved in the last decade for the treatment of PanNENs, the clinical outcome is improving. However, the appropriate selection or the effective combination of drugs has not been fully established. To conclude, management of PanNENs depends on various factors and further development of treatment strategies is required for improvement of survival outcome of patients with PanNENs.
PMID: 31864179 [PubMed - as supplied by publisher]